MARKET

MENS

MENS

Jyong Biotech Ltd.
NASDAQ
1.870
+0.210
+12.65%
After Hours: 1.810 -0.06 -3.21% 19:56 02/06 EST
OPEN
1.710
PREV CLOSE
1.660
HIGH
2.094
LOW
1.680
VOLUME
502.25K
TURNOVER
--
52 WEEK HIGH
67.00
52 WEEK LOW
1.655
MARKET CAP
142.17M
P/E (TTM)
-107.4713
1D
5D
1M
3M
1Y
5Y
1D
Jyong Biotech Appoints Veteran Capital Markets Executive Wei Zhang as Chief Financial Officer
TipRanks · 18h ago
Jyong Biotech Ltd. Appoints Wei Zhang as Chief Financial Officer
Reuters · 19h ago
Weekly Report: what happened at MENS last week (0126-0130)?
Weekly Report · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
Reuters · 01/30 18:38
BUZZ-U.S. STOCKS ON THE MOVE-Charter Communications, Western Digital, Regeneron
Reuters · 01/30 15:42
Jyong Biotech Announces Updated Statistical Analyses For Key Blood Biochemical Markers From Phase II Clinical Trial Of MCS-8 Conducted In Taiwan
Benzinga · 01/30 13:45
Jyong Biotech Reports Phase II Trial Results Showing MCS-8 Lowers Cholesterol and May Prevent Prostate Cancer
Reuters · 01/30 13:30
JYONG BIOTECH LTD - MCS-8 SHOWS 27.3% REDUCTION IN PROSTATE CANCER INCIDENCE
Reuters · 01/30 13:30
More
About MENS
Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.

Webull offers Jyong Biotech Ltd. stock information, including NASDAQ: MENS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MENS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MENS stock methods without spending real money on the virtual paper trading platform.